Cargando…

FDA review times for new drugs in ophthalmology

Detalles Bibliográficos
Autores principales:	Carpenter, Michelle A., Novack, Gary D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2020
Materias:	Pipeline
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417916/ https://www.ncbi.nlm.nih.gov/pubmed/32795591 http://dx.doi.org/10.1016/j.jtos.2020.08.003

Ejemplares similares

Expedited regulatory product approval in the time of COVID-19
por: Novack, Gary D.
Publicado: (2022)

Five variables that rule your life – Home mortgage and biostatistical power
por: Novack, Gary D.
Publicado: (2020)

Repurposing medications
por: Novack, Gary D.
Publicado: (2021)

What is an adequate and well controlled study?
por: Novack, Gary D.
Publicado: (2021)

Compounded medications for ocular surface disease
por: Lee, Edward H., et al.
Publicado: (2021)

Inotropes and Inodilators for Acute Heart Failure: Sarcomere Active Drugs in Focus
por: Nagy, László, et al.
Publicado: (2014)

Special features of RAD Sequencing data: implications for genotyping
por: Davey, John W, et al.
Publicado: (2013)

Targeting β(3)-Adrenergic Receptors in the Heart: Selective Agonism and β-Blockade
por: Cannavo, Alessandro, et al.
Publicado: (2017)

Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications
por: Altenberger, Johann, et al.
Publicado: (2018)

Use of Levosimendan in Cardiac Surgery: An Update After the LEVO-CTS, CHEETAH, and LICORN Trials in the Light of Clinical Practice
por: Guarracino, Fabio, et al.
Publicado: (2018)

EST Pipeline System: Detailed and Automated EST Data Processing and Mining
por: Xu, Hao, et al.
Publicado: (2003)

The JCSG high-throughput structural biology pipeline
por: Elsliger, Marc-André, et al.
Publicado: (2010)

TOPSAN: use of a collaborative environment for annotating, analyzing and disseminating data on JCSG and PSI structures
por: Krishna, S. Sri, et al.
Publicado: (2010)

Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II–III Systolic Heart Failure
por: Wohlford, George F., et al.
Publicado: (2021)

Investigational Anti–Atrial Fibrillation Pharmacology and Mechanisms by Which Antiarrhythmics Terminate the Arrhythmia: Where Are We in 2020?
por: Burashnikov, Alexander
Publicado: (2020)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Synthesis and clinical application of new drugs approved by FDA in 2022
por: Zhang, Jing-Yi, et al.
Publicado: (2023)

Nitric oxide: an old drug but with new horizons in ophthalmology—a narrative review
por: Lee, Soomin, et al.
Publicado: (2023)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
por: Dahlén, Amelia D., et al.
Publicado: (2022)

FDA relations during drug development
por: Mitchel, Jules T.
Publicado: (2000)

FDA and Its Role in Drug Development
por: Pazdur, Richard
Publicado: (2021)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

FDA in the Twenty-First Century: The Challenges of Regulating Drugs and New Technologies
por: Abbott, Ryan
Publicado: (2015)

FDA in the twenty-first century: the challenges of regulating drugs and new technologies
por: Abbott, Ryan
Publicado: (2016)

Recently FDA-approved drug: A new hope for vitiligo patients?
por: Siddiq, Mohammad Arham, et al.
Publicado: (2022)

FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review
por: Sochacka-Ćwikła, Aleksandra, et al.
Publicado: (2021)

Translating New Science Into the Drug Review Process: The US FDA’s Division of Applied Regulatory Science
por: Rouse, Rodney, et al.
Publicado: (2017)

Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

A New Paradigm for Uterine Fibroid Treatment: Transcervical, Intrauterine Sonography-Guided Radiofrequency Ablation of Uterine Fibroids with the Sonata System
por: Toub, David B.
Publicado: (2017)

Redeployment: a new paradigm for ophthalmology professionals
por: Attzs, Michelle S., et al.
Publicado: (2020)

FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis
por: Leo, Chandra P., et al.
Publicado: (2020)

New Truths in Ophthalmology
Publicado: (1896)

New Truths in Ophthalmology
Publicado: (1894)

Insights into Drug Cardiotoxicity from Biological and Chemical Data: The First Public Classifiers for FDA DICTrank
por: Seal, Srijit, et al.
Publicado: (2023)

Human radiolabeled mass balance studies supporting the FDA approval of new drugs
por: Ramamoorthy, Anuradha, et al.
Publicado: (2022)

Ophthalmology in the time of the Coronavirus pandemic
por: Macovei, Mioara-Laura
Publicado: (2021)

Review on fluorinated nucleoside/non-nucleoside FDA-approved antiviral drugs
por: Ismail, Magda M. F., et al.
Publicado: (2022)

Review of the Processes for FDA Oversight of Drugs, Medical Devices, and Combination Products
por: Sweet, Burgunda V., et al.
Publicado: (2011)

A review of FDA approved drugs and their formulations for the treatment of breast cancer
por: Chaurasia, Mohini, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_08gpih582bgshdsmtfuh9nefc0